Evidence map›Paper›PMID 34916485›Full record

ArticleSignal transduction and targeted therapy2021

An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity.

Yanping Wei, Xuewu Tang, Yibin Ren, Yun Yang, Fengliang Song, Jingbo Fu, Shuowu Liu, Miao Yu, Jing Chen, Suyang Wang and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. HMGB1: A Central Node in Cancer Therapy Resistance.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Yanping Wei *International Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Xuewu Tang *National Center for Liver Cancer, Shanghai, China.
Yibin Ren *International Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Yun Yang *The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Fengliang SongNational Center for Liver Cancer, Shanghai, China.
Jingbo FuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Shuowu LiuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Miao YuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Jing ChenInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Suyang WangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Kecheng ZhangDepartment of Biliary Tract Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Yexiong TanInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China.
Zhipeng HanNational Center for Liver Cancer, Shanghai, China.
Lixin WeiNational Center for Liver Cancer, Shanghai, China.
Baohua ZhangDepartment of Biliary Tract Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Zhangjun ChengHepato-Pancreato-biliary center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. chengzhangjun@seu.edu.cn.
Liang LiInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China. liliangyuanquan@163.com.
Hongyang WangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepato-Biliary Surgery Institute, Second Military Medical University, Shanghai, China. hywangk@vip.sina.com.ORCID 0000-0002-4709-3334
Second Military Medical University · CNZhongda Hospital Southeast University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the global leading cause of cancer-related deaths due to the deficiency of targets for precision therapy. A new modality of epigenetic regulation has emerged involving RNA-RNA crosstalk networks where two or more competing endogenous RNAs (ceRNAs) bind to the same microRNAs. However, the contribution of such mechanisms in HCC has not been well studied. Herein, potential HMGB1-driven RNA-RNA crosstalk networks were evaluated at different HCC stages, identifying the mTORC2 component RICTOR as a potential HMGB1 ceRNA in HBV

Indexed as

AnimalsB7-H1 AntigenCarcinogenesisCarcinoma, HepatocellularCell Line, TumorGlutamineHMGB1 ProteinImmunotherapyLiver Neoplasms, ExperimentalMiceMice, NudeNeoplasm ProteinsRapamycin-Insensitive Companion of mTOR ProteinRNA, NeoplasmB7-H1 AntigenCD274 protein, humanGlutamineHMGB1 ProteinHMGB1 protein, humanNeoplasm ProteinsRapamycin-Insensitive Companion of mTOR ProteinRICTOR protein, humanRNA, Neoplasm

Identifiers

PMID34916485
PMCPMC8677721
OpenAlexW4200261341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.